Trinity Biotech Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
05 May 2023 - 10:00PM
Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading
developer and manufacturer of diagnostic solutions for the
point-of-care and clinical laboratory markets, today reported the
receipt of a formal notification from The Nasdaq Stock Market LLC
("Nasdaq") that the Company has regained compliance with Listing
Rule 5450(a)(1), which requires the Company's ordinary shares to
maintain a minimum bid price of $1.00 per share. The Nasdaq staff
made this determination of compliance after the closing bid price
of the Company's ordinary shares was at $1.00 per share or greater
for the prior 10 consecutive business days. Accordingly, the
Company has regained compliance with Nasdaq Listing Rule 5450(a)(1)
and Nasdaq considers the prior bid price deficiency matter now
closed.
Forward-Looking Statements
Certain statements made in this release that are
not historical are forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. The words
“estimate”, “project”, “intend”, “expect”, “believe” and similar
expressions are intended to identify forward-looking statements.
These forward-looking statements involve known and unknown risks
and uncertainties. Many factors could cause the actual results,
performance or achievements of Trinity Biotech to be materially
different from any future results, performance or achievements that
may be expressed or implied by such forward-looking statements,
including, but not limited to, the results of research and
development efforts, risks associated with the outbreak and global
spread of the coronavirus (COVID-19), the effect of regulation by
the U.S. Food and Drug Administration and other agencies, the
impact of competitive products, product development
commercialization and technological difficulties. For additional
information regarding these and other risks and uncertainties
associated with Trinity Biotech’s business, reference is made to
our reports filed from time to time with the U.S. Securities and
Exchange Commission. We undertake no obligation to update or revise
any forward-looking statements for any reason.
About Trinity Biotech
Trinity Biotech develops, acquires, manufactures
and markets diagnostic systems, including both reagents and
instrumentation, for the point-of-care and clinical laboratory
segments of the diagnostic market. The products are used to detect
infectious diseases and to quantify the level of Haemoglobin A1c
and other chemistry parameters in serum, plasma and whole blood.
Trinity Biotech sells direct in the United States, Germany, France
and the U.K. and through a network of international distributors
and strategic partners in over 75 countries worldwide. For further
information, please see the Company's website:
www.trinitybiotech.com
Contact: |
Trinity Biotech plc |
Lytham
Partners, LLC |
|
John Gillard |
Joe Diaz |
|
(353)-1-2769800 |
(1)-602-889-9700 |
|
|
E-mail investorrelations@trinitybiotech.com |
Trinity Biotech (NASDAQ:TRIB)
Historical Stock Chart
From Apr 2024 to May 2024
Trinity Biotech (NASDAQ:TRIB)
Historical Stock Chart
From May 2023 to May 2024